Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01329744 · ClinicalTrials.gov registry record · Phase 1
Effects of IGF-I in HIV Metabolic Disease
A Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01329744 is a Phase 1 study that was terminated before completion, run by University of Texas Southwestern Medical Center. The registered enrollment target is 16 participants.
The verdict
NCT01329744, a Phase 1 study, was terminated before completion, sponsored by University of Texas Southwestern Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
This study examines the effects of recombinant insulin like growth factor - I on body composition, glucose homeostasis, and lipids, in adults with HIV infection and signs of metabolic disease.
Interventions
- DRUG Placebo control
- DRUG mecasermin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2011-06 |
| Est. Completion | 2013-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01329744
The ClinicalTrials.gov registry entry for NCT01329744 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo control is the first listed.
NCT01329744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01329744 about?
NCT01329744 is a clinical study titled "Effects of IGF-I in HIV Metabolic Disease". This study examines the effects of recombinant insulin like growth factor - I on body composition, glucose homeostasis, and lipids, in adults with HIV infection and signs of metabolic disease.
What is the current status of trial NCT01329744?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2011-06. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01329744?
The interventions under investigation include: Placebo control (DRUG), mecasermin (DRUG).
Who is sponsoring clinical trial NCT01329744?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.